Cleared Traditional

K982879 - SHIELD DIASTAT ANTI-B2 GLYCOPROTEIN 1 IGG (ELISA) ASSAY

K982879 is an FDA 510(k) clearance for SHIELD DIASTAT ANTI-B2 GLYCOPROTEIN 1 I..., manufactured by Shield Diagnostics, Ltd.. The device is a Class 2 Immunology device with product code MSV cleared through the Traditional 510(k) pathway after a 62-day FDA review.

K982879 · Shield Diagnostics, Ltd. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1998
Decision
62d
Days
Class 2
Risk

K982879 is an FDA 510(k) clearance for the SHIELD DIASTAT ANTI-B2 GLYCOPROTEIN 1 IGG (ELISA) ASSAY. Classified as System,test,antibodies,b2 - Glycoprotein I (b2 - Gpi) (product code MSV), Class II - Special Controls.

Submitted by Shield Diagnostics, Ltd. (Dundee, GB). The FDA issued a Cleared decision on October 15, 1998 after a review of 62 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Shield Diagnostics, Ltd. devices

FDA 510(k) Submission Details - K982879

510(k) Number K982879 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 14, 1998
Decision Date October 15, 1998
Days to Decision 62 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
43d faster than avg
Panel avg: 105d · This submission: 62d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MSV Device Classification - Class 2, Special Controls

Product Code MSV System,test,antibodies,b2 - Glycoprotein I (b2 - Gpi)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MSV System,test,antibodies,b2 - Glycoprotein I (b2 - Gpi)

All 35
Devices cleared under the same product code (MSV) and FDA review panel - the closest regulatory comparables to K982879.
REAADS IGA ANTI-B2GP 1 TEST KIT
K982434 · Corgenix, Inc. · Dec 1998
REAADS IGG ANTI-B2GPI TEST KIT
K982391 · Corgenix, Inc. · Dec 1998
REAADS IGM ANTI-B2GP1 TEST KIT
K982433 · Corgenix, Inc. · Dec 1998
QUANTA LITE B2 GPI SCREEN
K980230 · Inova Diagnostics, Inc. · Mar 1998
THE THERATEST EL-B2GP1 (IGM, IGG, IGA) AND EL-B2GP1SCR
K972790 · Theratest Laboratories, Inc. · Dec 1997
EL-B2GP1SCR
K973882 · Theratest Laboratories, Inc. · Dec 1997